|
Onco-Biotechnology - Research, Clinical and Business Summit
Agenda
Complete Agenda (PDF format) 
THURSDAY, JULY 24, 2008
| 8:00 - 8:30 |
Coffee and Rolls |
| 8:30 - 8:45 |
Onco-Biotechnology Summit - Welcoming Remarks
Steven T. Rosen, MD, FACP, Director, Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Alicia Löffler, Ph.D., Director and Professor, Kellogg Center for Biotechnology |
| 8:45 - 9:45 |
Panel: Evolution of Myeloma Treatments and Continuing Challenges
Seema Singhal, MD, Northwestern University
Robert Knight, MD, VP Research and Development,Oncology at Celgene
David Schenkein, MD, SVP, Clinical Hematology/Oncology at Genentech
Jayesh Mehta, MD and Professor Feinberg School of Medicine |
| 9:45 - 10:45 |
How Understanding the Biology of Non-Hodgkin's Lymphoma Influences Therapy
Leo I. Gordon, MD, Northwestern University
David Schenkein, MD, SVP, Clinical Hematology/Oncology at Genentech
Michael Werner, lymphoma patient, Board member of Lymphoma Research Foundation |
| 10:45 - 11:00 |
Break |
| 11:00 - 12:00 |
Panel: Payers Perspective on Onco-Biotechnology
Moderator: Christine Weldon, Center for Business Models in Healthcare
Lee Newcomer, MD, United HealthCare
Steve Russek, R.Ph. Chief Clinical Officer for the Accredo Health Group, the Specialty Pharmacy unit of Medco
Bruce Quinn, M.D., Ph.D., MBA, Foley Hoag - formerly the Contractor Medical Director for the California Medicare Part B
Al B. Benson III, M.D. Northwestern University |
| 12:00 - 1:00 |
What is on the Horizon for Solid Tumors - Personalized Medicine Pipeline
Jyoti D. Patel, MD- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
George R. Simon, MD, FACP, FCCP, H. Lee Moffitt Cancer Center & Research Institute
Susan Guba, MD, Medical Advisor at Eli Lilly |
| 1:00 - 2:00 |
Lunch |
| 2:00 - 2:45 |
Keynote Presentation 1: How New and Emerging Biotechnology Impacts Practice Management
Howard "Skip" A. Burris III, M.D. , Chief Medical Officer, Sara Cannon Research Institute |
| 2:45 - 3:45 |
Panel: Novel Treatment Modalities in Breast Cancer
Virginia Kaklamani, MD, Northwestern University
Olufunmilayo I. Olopade, MD, FACP Professor of Medicine and Human Genetics and Director, Cancer Risk Clinic University of Chicago Hospitals
Howard "Skip" A. Burris III, M.D. , Chief Medical Officer, Sara Cannon Research Institute |
| 3:45 - 4:00 |
Break |
| 4:00 - 5:00 |
Panel: Biotechnology Investments, Capital and Partnerships - Present and Future
Moderator: Alicia Löffler, Ph.D., Director and Professor Kellogg Center for Biotechnology
Steve Elms - Aisling Capital
Elizabeth Bachert - Pfizer
David Hirsch – Founder and Principal; Longitude Capital Investments |
| 5:00 - 6:30 p.m. |
Networking Reception |
FRIDAY, JULY 25, 2008
| 7:30 - 8:30 |
Coffee and Rolls |
| 8:30 - 9:30 |
Keynote Presentation: FDA perspective on Onco-Biotechnology
Richard Pazdur, M.D. –Director of the Office of Oncology Drug Products, Center for Drug Evaluation (CDER), FD |
| 9:30 - 10:30 |
Presentation or Panel Discussion: Adverse Drug Reactions with a focus on identifying toxicities to novel agents
Moderator: Charles L. Bennett, MD, PhD - Northwestern University
Steven Hirschfeld, M.D., Ph.D. Oncology Group Leader, Office of Cellular and Gene Therapy, Center for Biologics Evaluation and Research, FDA
Janet Lee Nichol, Biotechnology Consultant |
| 10:30 - 11:30 |
Panel Discussion: Cancer Prevention and Survivorship...
Michael N. Liebman, Ph.D., Windber Research Institute
Linda Malkas, Ph.D, Indiana University School of Medicine
Kay Wissmann, Breast Cancer Network of Strength, formerly known as Y-ME National Breast Cancer Organization |
| 11:30 - 12:00 |
Snack Break |
| 12:00 - 1:00 |
Presentation: Nanotechnology Pipeline Impact on Cancer Diagnostics and Therapeutics
Dr. Piotr Grodzinski, Director of Nanotechnology for Cancer programs at the Alliance for Nanotechnology in Cancer of the National Cancer Institute |
| 1:00 - 2:00 |
Integration of New Agents for Acute Leukemia, CML and CLL into Clinical Practice
Moderators: Martin S. Tallman, MD - Northwestern University
Michael Vasconcelles, MD - Vice President, Clinical Research Genzyme Oncology
Charles A. Schiffer, MD - Wayne State University
Olga Frankfurt, MSCI, MD - Northwestern University |
| 2:00 - 2:30 |
Conclusion of Summit |
Each oncology topic will include brief info on:
- Epidemiology of disease
- Modern diagnostic and therapeutic options
- Horizon of diagnostics and therapeutics including mechanism of action and anticipated results
- Biotech representation of the pipeline
The agenda topics, presenters/panelists and times are subject to change
|
